Role of MicroRNAs in NAFLD/NASH

Digestive Diseases and Sciences

Volumn 61, Issue 5, 2016, Pages 1314-1324

  Szabo, Gyongyi ^a   Csak, Timea ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

MicroRNAs; NAFLD; NASH

Indexed keywords

MICRORNA; BIOLOGICAL MARKER;

ADIPOSE TISSUE; APOPTOSIS; CELL COMMUNICATION; CELL PROLIFERATION; CHOLESTEROL METABOLISM; DISEASE COURSE; EXOSOME; FATTY LIVER; HEPATITIS; HUMAN; INTESTINE FLORA; LIPID METABOLISM; LIVER FIBROSIS; MEMBRANE MICROPARTICLE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PHYSIOLOGY;

BIOMARKERS; FATTY LIVER; GENE EXPRESSION REGULATION; HUMANS; METABOLIC SYNDROME X; MICRORNAS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84954325304     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-4002-4     Document Type: Review

References (141)

1. Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–355.
2. Bartel DP. MicroRNA target recognition and regulatory functions. Cell. 2009;136:215–233.
3. Bala S, Marcos M, Kodys K, et al. Up-regulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor alpha (TNF{alpha}) production via increased mRNA half-life in alcoholic liver disease. J Biol Chem. 2011;286:1436–1444.
4. Orom UA, Nielsen FC, Lund AH. Microrna-10a binds the 5′UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell. 2008;30:460–471.
5. Ohtsuka M, Ling H, Doki Y, Mori M, Calin GA. MicroRNA processing and human cancer. J Clin Med. 2015;4:1651–1667.
6. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–854.
7. Londin E, Loher P, Telonis AG, et al. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proc Natl Acad Sci USA. 2015;112:E1106–E1115.
8. Szabo G, Bala S. MicroRNAs in liver diseases. Nat Rev Gastroenterol Hepatol. 2013;10:542–552.
9. Maffioletti E, Tardito D, Genarelli M, Bocchio-Chiavetto L. Micro spies from the brain to the periphery: new clues from studies on microRNAs in neuropsychiatric disorders. Front Cell Neurosci. 2014;8:75.
10. Cheung O, Puri I, Eicken C, et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology. 2008;48:1810–1820.
11. Feng YY, Xu XQ, Ji CB, Shi CM, Guo XR, Fu JF. Aberrant hepatic microRNA expression in nonalcoholic fatty liver disease. Cell Physiol Biochem. 2014;34:1983–1997.
12. Karere GM, Glenn JP, VandeBerg JL, Cox LA. Differential microRNA response to a high-cholesterol, high-fat diet in livers of low and high LDL-C baboons. BMC Genom. 2012;13:320.
13. Dolganiuc A, Petrasek J, Kodys K, et al. MicroRNA expression profile in Lieber–DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice. Alcohol Clin Exp Med. 2009;33:1704–1710.
14. Wang B, Majumder S, Nuovo G, et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology. 2009;50:1152–1161.
15. Hoekstra M, van der Sluis RJ, Kuiper J, Van Berkel TJ. Nonalcoholic fatty liver disease is associated with an altered hepatocyte microRNA profile in LDL receptor knockout mice. J Nutr Biochem. 2012;23:622–628.
16. Enache LS, Enache EL, Ramiere C, et al. Circulating RNA molecules as biomarkers in liver disease. Int J Mol Sci. 2014;15:17644–17666.
17. Turchinovich A, Weiz L, Langheinz A, Bruwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;39:7223–7233.
18. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997–1006.
19. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513–10518.
20. Weber JA, Baxter DH, Zhang S, et al. The microRNA spectrum in 12 body fluids. Clin Chem. 2010;56:1733–1741.
21. Arrojo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA. 2011;108:5003–5008.
22. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13:423–433.
23. Lee Y, El Andaloussi S, Wood MJ. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet. 2012;21:R125–R134.
24. Turchinovich A, Burwinkel B. Distinct AGO1 and AGO2 associated miRNA profiles in human cells and plasma. RNA Biol. 2012;9:1066–1075.
25. Bala S, Petrasek J, Mundkur S, et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology. 2012;56:1946–1957.
26. Pirola CJ, Fernandez-Gianotti T, Castano GO, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64:800–812.
27. Yamada H, Suzuki K, Ichino N, et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta. 2013;424:99–103.
28. Csak T, Bala S, Lippai D, et al. microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis. Liver Int. 2015;35:532–541.
29. Tan Y, Ge G, Pan T, Wen D, Gan J. A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. PLoS ONE. 2014;9:e105192.
30. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654–659.
31. Bala S, Csak T, Momen-Heravi F, et al. Biodistribution and function of extracellular miRNA-155 in mice. Sci Rep. 2015;5:10721.
32. Arner P, Kulyte A. MicroRNA regulatory networks in human adipose tissue and obesity. Nat Rev Endocrinol. 2015;11:276–288.
33. Ge Q, Brichard S, Yi X, Li Q. microRNA as a new mechanism regulating adipose tissue inflammation in obesity and as a novel therapeutic strategy in the metabolic syndrome. J Immunol Res. 2014; ID: 987285.
34. Abente EJ, Subramanian M, Ramachandran V, Najafi-Shoushtari SH. MicroRNAs in obesity-associated disorders. Arch Biochem Biophys. 2015. doi:10.1016/j.abb.2015.09.018.
35. Schneeberger M, Gomez-Valades AG, Ramirez S, Gomis R, Claret M. Hypothalamic miRNAs: emerging roles in energy balance control. Front Neurosci. 2015;9:41.
36. Chen H, Lan HY, Roukos DH, Cho WC. Application of mircroRNAs in diabetes mellitus. J Endocrinol. 2014;222:R1–R10.
37. Chakraborty C, Doss CGP, Bandyopadhyay S, Agoramoorthy G. Influence of miRNA in insulin signaling pathway and insulin resistance: micro-molecules with major role in type-2 diabetes. WIREs RNA. 2014;5:697–712.
38. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52:1836–1846.
39. Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis. 2015;239:192–202.
40. Estep M, Armistead D, Hossain N, et al. Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2010;32:487–497.
41. Sharma H, Estep M, Birerdinc A, et al. Expression of genes for microRNA-processing enzymes is altered in advanced non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2013;28:1410–1415.
42. Li S, Chen X, Zhang H, et al. Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J Lipid Res. 2009;50:1756–1765.
43. Katsura A, Morishita A, Iwama H, et al. MicroRNA profiles following metformin treatment in a mouse model of non-alcoholic steatohepatitis. Int J Mol Med. 2015;35:877–884.
44. Kita Y, Takamura T, Misu H, et al. Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. PLoS ONE. 2012;7:e43056.
45. Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006;3:87–98.
46. Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in nonhuman primates. Nature. 2008;452:896–899.
47. Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. miR-122—a key factor and therapeutic target in liver disease. J Hepatol. 2015;2:448–457.
48. Wilson JA, Sagan SM. Hepatitis C virus and human miR-122: insights from the bench to the clinic. Curr Opin Virol. 2014;7:11–18.
49. Tsai WC, Hsu SD, Hsu CS, et al. MicroRNA-122 plays critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest. 2012;122:2884–2897.
50. Hsu SH, Wang B, Kota J, et al. Essential metabolic, antiinflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest. 2012;122:2871–2883.
51. Csak T, Bala S, Lippai D, et al. MicroRNA-155 deficiency attenuates liver steatosis and fibrosis without reducing inflammation in a mouse model of steatohepatitis. PLoS ONE. 2015;10:e0129251.
52. Miller AM, Gilchrist DS, Nijjar J, et al. MiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice. PLoS ONE. 2013;8:e72324.
53. Sun C, Huang F, Liu X, et al. miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR. Int J Mol Med. 2015;35:847–853.
54. Ahn J, Lee H, Jung CH, Ha T. Lycopene inhibits hepatic steatosis via microRNA-21-induced downregulation of fatty acid-binding protein 7 in mice fed a high-fat diet. Mol Nutr Food Res. 2012;56:1665–1674.
55. Loyer X, Paradis V, Henique C, et al. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression. Gut. 2015. doi:10.1136/gutjnl-2014-308883.
56. Najafi-Shoushtari SH, Kristo F, Li Y, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science. 2010;28:1566–1569.
57. Allen RM, Marquart TJ, Albert CJ, et al. miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity. EMBO Mol Med. 2012;4:882–895.
58. Li T, Francl JM, Boehme S, Chiang JYL. Regulation of cholesterol and bile acid homeostasis by the CYP7A1/SREBP2/miR-33a axis. Hepatology. 2013;58:1111–1121.
59. Horie T, Nishino T, Baba O, et al. MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice. Nat Commun. 2013;4:2883.
60. Lee J, Padhye A, Sharma A, et al. A pathway involving farnesoid X receptor and small heterodimer partner positively regulates hepatic sirtuin 1 levels via microRNA-34a inhibition. J Biol Chem. 2010;285:12604–12611.
61. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA. 2008;105:13421–13426.
62. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating MicroRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS ONE. 2011;6:e23937.
63. Ng R, Wu H, Xiao H, et al. Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. Hepatology. 2014;60:554–564.
64. Vincent R, Sanyal A. Recent advances in understanding of NASH: microRNAs as both biochemical markers and players. Curr Pathibiol Rep. 2014;2:109–115.
65. Lee HM, Nguyen DT, Lu LF. Progress and challenge of microRNA research in immunity. Front Genet. 2014;5:178.
66. Tili E, Michaille JJ, Costinean S, Corce CM. MicroRNAs, the immune system and rheumatic disease. Nat Clin Pract Rheumatol. 2008;4:534–541.
67. Du J, Niu X, Wang Y, et al. MiR-146a-5p suppresses activation and proliferation of hepatic stellate cells in nonalcoholic fibrosing steatohepatitis through directly targeting Wnt1 and Wnt5a. Sci Rep. 2015;5:16163.
68. Hur W, Lee JH, Kim SW, et al. Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK/Akt pathway. Int J Biochem Cell Biol. 2015;64:265–276.
69. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012;56:1384–1391.
70. Wu H, Ng R, Chen X, Steer CJ, Song G. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut. 2015. doi:10.1136/gutjnl-2014-308430.
71. Zhang J, Jiao J, Cermelli S, et al. miR-21 inhibition reduces liver fibrosis and prevents tumor development by inducing apoptosis of CD24 + progenitor cells. Cancer Res. 2015;75:1859–1867.
72. Zhao J, Tang N, Wu K, et al. MiR-21 simultaneously regulates ERK1 signaling in HSC activation and hepatocyte EMT in hepatic fibrosis. PLoS ONE. 2014;9:e108005.
73. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010;17:193–199.
74. Corey KE, Misdraji J, Gelrud L, et al. Obstructive sleep apnea is associated with nonalcoholic steatohepatitis and advanced live histology. Dig Dis Sci. 2015;60:2523–2528.
75. Ahmed MH, Byrne CD. Obstructive sleep apnea syndrome and fatty liver: association or casual link? World J Gastroenterol. 2010;16:4243–4252.
76. Momen-Heravi F, Saha B, Kodys K, Catalano D, Satishchandran A, Szabo G. Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcoholic hepatitis. J Transl Med. 2015;13:261.
77. Schutte K, Schultz C, Link A, Malfertheiner P. Current biomarkers for hepatocellular carcinome: surveillance, diagnosis and prediction of prognosis. World J Gastroenterol. 2015;7:139–149.
78. Gori M, Arciello M, Balsano C. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma. Biomed Res Int. 2014;2014:741465.
79. Nakao K, Miyaaki H, Ichikawa T. Antitumor function of microRNA-122 against hepatocellular carcinoma. J Gastroenterol. 2014;49:589–593.
80. Callegari E, Gramantieri L, Domenicali M, D’Abundo L, Sabbioni S, Negrini M. MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell Death Differ. 2015;22:46–57.
81. Chartoumpekis DV, Zaravinos A, Ziros PG, et al. Differential expression of microRNAs in adipose tissue after long-term high fat diet-induced obesity in mice. PLoS ONE 2012;7. ID: e34872.
82. Ortega FJ, Moreno-Navarrete JM, Pardo G, et al. MiRNA expression profile of human subcutaneous adipose and during adipocyte differentiation. PLoS ONE 2010;5. ID: e9022.
83. Kloting N, Berthold S, Kovacs P, et al. MicroRNA expression in human omental and subcutaneous adipose tissue. PloS ONE 2009;4. ID e4699.
84. Heneghan HM, Miller N, McAnenea OJ, O’Brian T, Kerin MJ. Differential miRNA expression in omental adipose and in the circulation of obese patients identifies novel metabolic biomarkers. J Clin Endocrin Metab. 2011;96:E846–E850.
85. Son YH, Ka S, Kim AY, Kim JB. Regulation of adipocyte differentiation via mircoRNAs. Endocrinol Metab (Seoul). 2014;29:122–135.
86. Strum JC, Johnson JH, Ward J, et al. MicroRNA 132 regulates nutritional stress-induced chemokine production through repression of SirT1. Mol Endocrinol. 2009;23:1876–1884.
87. Parra P, Serra E, Palou A, et al. Expression of adipose MicroRNA is sensitive to dietary conjugated linoleic acid treatment in mice. PLoS ONE 2010;5. ID: e13005.
88. Arner E, Mejhert N, Kulyte A, et al. Adipose tissue microRNAs as regulators of CCL2 production in human obesity. Diabetes. 2012;61:1986–1993.
89. Zhuang G, Meng C, Guo X, et al. A novel regulator of macrophage activation: miR-223 in obesity associated adipose tissue inflammation. Circulation. 2012;125:2892–2903.
90. Ge Q, Gerard J, Noel L, Scroyen I, Brichard SM. MicroRNAs regulated by adiponectin as novel targets for controlling adipose tissue inflammation. Endocrinology. 2012;153:5285–5296.
91. Ogawa R, Tanaka C, Sato M, et al. Adipocyte-derived microvesicles contain RNA that is transported into macrophages and might be secreted into blood circulation. BBRC. 2010;398:723–729.
92. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9:313–323.
93. Turnbaugh PJ, Hamadt M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457:480–484.
94. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027–1031.
95. Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482:179–185.
96. Henao-Mejia J, Elinav E, Thaiss CA, Flavell RA. The intestinal microbiota in chronic liver diseases. Adv Immunol. 2013;117:73–97.
97. Agel B, DiBaise JK. Role of gut microbiome in nonalcoholic fatty liver disease. Nutr Clin Pract. 2015;30:780–786.
98. Quigley EM, Monsour HP. The gut microbiota and nonalcoholic fatty liver disease. Semin Liver Dis. 2015;35:262–269.
99. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–1772.
100. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877–1887.
101. Vijay-Kumat M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010;328:228–231.
102. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003;37:343–350.
103. Velayudham A, Dolagniuc A, Ellis M, et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology. 2009;49:989–997.
104. Runtsch MC, Round JL, O’Connell RM. MicroRNAs and the regulation of intestinal homeostasis. Front Genet. 2014;5. ID: 347.
105. Biton M, Levin A, Slyper M, et al. Epithelial microRNAs regulate gut mucosal immunity via epithelium-T cell crosstalk. Nat Immunol. 1994;12:239–246.
106. Ye D, Guo S, Al-Sadi R, Ma TY. MicroRNA regulation of intestinal epithelial tight junction permeability. Gastroenterology. 2011;141:132–1333.
107. Clare S, John V, Walker AW, et al. Enhanced susceptibility to Citrobacter rodentium infection in mircroRNA-155-deficient mice. Infect Immun. 2013;81:723–732.
108. Lippai D, Bala S, Catalano D, Kodys K, Szabo G. Micro-RNA-155 deficiency prevents alcohol-induced serum endotoxin increase and small bowel inflammation in mice. Alcohol Clin Exp Res. 2014;38:2217–2224.
109. Das LM, Torres-Castillo MDLA, Gill T, Levine AD. TGFβ conditions intestinal T cells to express increased levels of miR-155, associated with downregulation of IL-2 and itk mRNA. Mucosal Immunol. 2013;6:167–176.
110. Brain O, Owens BMJ, Pichulik T, et al. The intracellular sensor NOD2 induces microRNA-29 expression in human dendritic cells to limit IL-23 release. Immunity. 2013;39:521–536.
111. Giles DA, Moreno-Fernandez ME, Divanovic S. IL-17 axis driven inflammation in non-alcoholic fatty liver disease progression. Curr Drug Targets. 2015;16:1315–1323.
112. Takahashi H, Kanno T, Nakayamada S, et al. TGFβ and retinoic acid induce the microRNA miR-10a, which targets bcl-6 and constrains the plasticity of helper T cells. Nat Immunol. 2012;13:587–595.
113. Reavan GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 1998;37:1595–1607.
114. Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–438.
115. Billiet L, Doaty S, Katz JD, Velasquez MT. Review of hyperuricemia as new marker for metabolic syndrome. ISRN Rheumatol. 2014;2014:852954.
116. Serafino-Agrusa L, Spatafora M, Scichilone N. Asthma and metabolic syndrome: current knowledge and future perspectives. World J Clin Cases. 2015;3:285–292.
117. Seetho IW, Wilding JP. Sleep-disordered breathing, type 2 diabetes and the metabolic syndrome. Chron Respir Dis. 2014;11:257–275.
118. Baldani DP, Skrgatic L, Ouquaq R. Polycystic ovary syndrome: important underrecognized cardiometabolic risk factor in reproductive-age women. Int J Endocrinol. 2015;2015:786362.
119. Kaya E, Sikka SC, Gur S. A comprehensive review of metabolic syndrome affecting erectile dysfunction. J Sex Med. 2015;12:856–875.
120. Voiculescu VM, Lupu M, Papagheorghe L, Giurcaneanu C, Micu E. Psoriasis and metabolic syndrome—scientific evidence and therapeutic implications. J Med Life. 2014;7:468–471.
121. Ganzetti G, Campanati A, Offidani A. Non-alcoholic fatty liver disease and psoriasis: so far, so near. World J Hepatol. 2015;7:315–326.
122. Prasad GV. Metabolic syndrome and chronic kidney disease: current status and future directions. World J Nephrol. 2014;3:210–219.
123. Legakis I, Syrigos K. Obesity modulation—the role in carcinogenesis. Anticancer Agents Med Chem. 2010;10:481–490.
124. Nishiguchi T, Imanishi T, Akasaka T. MicroRNAs and cardiovascular diseases. BioMed Res Int 2015; ID: 682857.
125. Pua HH, Ansel KM. MicroRNA regulation of allergic inflammation and asthma. Curr Opin Immunol. 2015;36:101–108.
126. Ebrahimi A, Sadroddiny E. MicroRNAs in lung diseases: recent findings and their pathophysiological implications. Pulm Pharmacol Ther. 2015;34:55–63.
127. Sorensen AE, Wissing ML, Salo S, Englund AL, Dalgaard LT. MicroRNAs related to polycystic ovary syndrome (PCOS). Genes (Basel). 2014;5:684–708.
128. Xia J, Zhang W. microRNAs in normal and psoriatic skin. Physiol Genomics. 2014;46:113–122.
129. Trionfini P, Benigni A, Remuzzi G. MicroRNAs in kidney physiology and disease. Nat Rev Nephrol. 2015;11:23–33.
130. Iracheta-Vellve A, Petrasek J, Satishchandran A, et al. Inhibition of sterile danger signals, uric acid and ATP, prevents inflammasome activation and protects from alcoholic steatohepatitis in mice. J Hepatol. 2015;63:1147–1155.
131. Petrasek J, Iracheta-Vellve A, Saha B, et al. Metabolic danger signals, uric acid and ATP, mediate inflammatory cross-talk between hepatocytes and immune cells on alcoholic liver disease. J Leukoc Biol. 2015;98:249–256.
132. Rock KL, Kataoka H, Lai JJ. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol. 2013;9:13–23.
133. Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol. 2015;12:387–400.
134. Baldwin W, McRahe S, Marek G, et al. Hyperuricaemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes. 2011;60:1258–1269.
135. Johnson RJ, Nakagawa T, Sanchez-Lozada LG, et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes. 2013;62:3307–3315.
136. Sun DQ, Wu SJ, Liu WY, et al. Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease. Expert Opin Ther Targets. 2015;30:1–13.
137. Lin H, Li Q, Liu X, et al. Liver fat content is associated with elevated serum uric acid in the Chinese middle-aged and elderly populations: Shanghai Changfeng Study. PLoS ONE. 2015;10:e40379.
138. Dalbeth N, Pool B, Shaw OM, et al. Role of miR-146a in regulation of the acute inflammatory response to monosodium urate crystals. Ann Rheum Dis. 2015;74:786–790.
139. Yu S, Hong Q, Wang Y, et al. High concentrations of uric acid inhibit angiogenesis via regulation of the Kruppel-Like-Factor 2-Vascular Endothelial Growth Factor-A axis by miR-92a. Circ J. 2015; PMID: 26299712.
140. Hong Q, Yu S, Geng X, et al. High concentrations of uric acid inhibit endothelial cell migration via miR-663 which regulates phosphatase and tensin homolog by targeting transforming growth factor-β1. Microcirculation. 2015;22:306–314.
141. Ciupinska-Kajor M, Hartleb M, Kajor M, et al. Hepatic angiogenesis and fibrosis are common features in morbidly obese patients. Hepatol Int. 2013;7:233–240.